| Upcoming events on CSL LIMITED |
|
| 02/16/21 | | Interim 2021 Earnings Release |
| 08/18/21 | | FY 2021 Earnings Release (Projected) |
| 10/12/21 | | Annual General Meeting |
| 02/16/22 | | Interim 2022 Earnings Release (Projected) |
|
| Past events on CSL LIMITED |
|
| 10/21/20 | | Infectious Disease Society of America ID Week Meeting |
| 10/19/20 | 06:00pm | | R&D Day |
| 10/13/20 | 07:00pm | | Annual General Meeting |
| 09/10/20 | | Ex-dividend day for final dividend |
|
| Upcoming sector events for CSL LIMITED |
|
|
| |
|
| Past sector events for CSL LIMITED |
|
|
|
|
|
| Annual results | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 (e) |
Sales
M $ |
Released
Forecast
Spread | 6 115
6 249
-2,1% | 6 923
6 877
0,66% | 7 915
7 730
2,4% | 8 539
8 493
0,53% | 9 151
9 224
-0,79% |
10 127
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 1 749
1 836
-4,7% | 2 048
2 096
-2,3% | 2 677
2 596
3,1% | 2 879
2 911
-1,1% | 3 136
3 204
-2,1% |
3 440
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 1 529
1 630
-6,2% | 1 769
1 835
-3,6% | 2 380
2 296
3,7% | 2 504
2 575
-2,8% | 2 717
2 781
-2,3% |
2 982
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 1 556
1 663
-6,4% | 1 690
1 755
-3,7% | 2 281
2 191
4,1% | 2 341
2 420
-3,3% | 2 573
2 651
-3,0% |
2 820
|
Net income
M $ |
Released
Forecast
Spread | 1 242
1 279
-2,9% | 1 337
1 358
-1,5% | 1 729
1 704
1,4% | 1 919
1 908
0,57% | 2 103
2 115
-0,61% |
2 254
|
EPS
$ |
Released
Forecast
Spread | 2,68
2,79
-3,9% | 2,94
2,98
-1,6% | 3,81
3,78
0,81% | 4,23
4,21
0,43% | 4,62
4,65
-0,84% |
4,95
| | Announcement Date | 08/16/2016 | 08/15/2017 | 08/14/2018 | 08/13/2019 | 08/18/2020 | |
|
|
|
| Quarterly results | 2016 S1 | 2016 S2 | 2017 S1 | 2017 S2 | 2018 S1 | 2018 S2 | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 (e) | 2021 S2 (e) | 2022 S1 (e) | 2022 S2 (e) | 2023 S1 (e) |
Sales
M $ |
Released
Forecast
Spread | 3 136
2 910
7,8% | 2 980
3 073
-3,1% | 3 677
3 625
1,4% | 3 246
3 230
0,50% | 4 147
3 927
5,6% | 3 768
3 554
6,0% | 4 505
4 514
-0,20% | 4 034
4 024
0,24% | 4 911
4 821
1,9% | 4 240
4 347
-2,4% |
5 509
|
4 642
|
5 805
|
4 966
|
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 960
910
5,5% | 789
915
-14% | 1 226
1 183
3,6% | 822
942
-13% | 1 617
1 313
23% | 1 060
975
8,7% | 1 719
1 768
-2,8% | 1 160
1 163
-0,26% | 1 836
1 896
-3,1% | 1 300
1 281
1,5% |
2 129
|
1 259
|
2 136
|
1 472
|
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 867
808
7,2% | 662
806
-18% | 1 095
1 052
4,1% | 674
778
-13% | 1 476
1 155
28% | 904
837
8,0% | 1 553
1 599
-2,9% | 951
1 093
-13% | 1 632
1 689
-3,4% | 1 085
1 079
0,51% |
1 920
|
1 060
|
1 931
|
1 269
|
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 895
770
16% |
| 1 057
1 017
3,9% |
|
| 857
749
14% | 1 460
1 569
-6,9% | 881
947
-7,0% | 1 561
1 611
-3,1% | 1 011
1 007
0,44% |
1 843
|
983
|
1 849
|
1 188
|
|
Net income
M $ |
Released
Forecast
Spread | 719
730
-1,5% | 524
574
-8,8% | 806
800
0,78% | 531
588
-9,7% | 1 086
866
25% | 643
631
2,0% | 1 161
1 202
-3,4% | 758
751
0,87% | 1 248
1 296
-3,7% | 855
805
6,1% |
1 448
|
777
|
1 460
|
938
|
|
EPS
|
Released
Forecast
Spread |
|
| 1,77
1,75
1,0% | 1,17
1,29
-9,8% | 2,40
1,85
30% | 1,41
1,39
1,4% | 2,56
2,65
-3,5% | 1,67
1,67
0,04% | 2,74
2,89
-5,2% | 1,88
1,93
-2,8% |
3,18
|
1,79
|
3,29
|
2,00
|
3,71
| | Announcement Date | 02/15/2016 | 08/16/2016 | 02/15/2017 | 08/15/2017 | 02/13/2018 | 08/14/2018 | 02/12/2019 | 08/13/2019 | 02/11/2020 | 08/18/2020 | | | | | |
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
|
AstraZeneca shares fall on 'hefty' $39-billion Alexion deal |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
Previous period
